Portfolio

Aisling Capital invests in products, technologies and businesses that advance health.
In addition to investing in companies developing pharmaceutical, biotechnology and medical products, Aisling invests in businesses that provide drug development, manufacturing and other important services to the healthcare industry.

Portfolio Companies

  • Adams Respiratory Therapeutics, Inc.

    Specialty pharmaceutical company engaged in the development, commercialization and marketing of over-the-counter and prescription drugs for the treatment of respiratory disorders
    • Year Invested

      2001
    • Fund

      I
    • Sector

      Consumer
    • Company Status

      acquired
    • Investment Status

      historic
    • Location

      Chester, NJ
    • Website

      rb.com
  • ADMA Biologics, Inc.

    NasdaqCM:ADMA
    Biopharmaceutical company that develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of infectious diseases
    • Year Invested

      2007
    • Fund

      II
    • Sector

      Biopharma
    • Company Status

      public
    • Investment Status

      current
    • Location

      Ramsey, NJ
    • Website

      admabiologics.com
  • Advion, Inc.

    Provider of bioanalytical testing equipment to the pharmaceutical industry
    • Year Invested

      2002
    • Fund

      I
    • Sector

      Services
    • Company Status

      private
    • Investment Status

      current
    • Location

      Ithaca, NY
    • Website

      advion.com
  • Agile Therapeutics, Inc.

    NasdaqGM:AGRX
    Women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products
    • Year Invested

      2012
    • Fund

      III
    • Sector

      Biopharma
    • Company Status

      public
    • Investment Status

      current
    • Location

      Princeton, NJ
    • Website

      agiletherapeutics.com
  • Allos Therapeutics, Inc.

    Biopharmaceutical company engaged in the development and commercialization of anti-cancer therapeutics
    • Year Invested

      2002
    • Fund

      I
    • Sector

      Biopharma
    • Company Status

      acquired
    • Investment Status

      historic
    • Location

      Westminster, CO
    • Website

      sppirx.com
  • Ambit Biosciences Corporation

    Biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat oncology, autoimmune and inflammatory diseases
    • Year Invested

      2001
    • Fund

      I
    • Sector

      Biopharma
    • Company Status

      acquired
    • Investment Status

      historic
    • Location

      San Diego, CA
    • Website

      ambitbio.com
  • Aragon Pharmaceuticals, Inc.

    Oncology drug development company focused on novel therapeutics for prostate and breast cancer
    • Year Invested

      2010
    • Fund

      III
    • Sector

      Biopharma
    • Company Status

      acquired
    • Investment Status

      historic
    • Location

      New Brunswick, NJ
    • Website

      jnj.com
  • Archimica Cooperatief U.A.

    Manufacturer of active pharmaceutical ingredients and late state intermediates for the pharmaceutical industry
    • Year Invested

      2006
    • Fund

      II
    • Sector

      Services
    • Company Status

      acquired
    • Investment Status

      historic
    • Location

      Amsterdam, Netherlands
    • Website

      euticals.com
  • ARMGO Pharma, Inc.

    Biopharmaceutical company dedicated to the discovery and development of novel small-molecule therapeutics to treat debilitating cardiac, muscular and neurological disorders
    • Year Invested

      2006
    • Fund

      II
    • Sector

      Biopharma
    • Company Status

      private
    • Investment Status

      current
    • Location

      Tarrytown, NY
    • Website

      armgo.com
  • Aton Pharma, Inc.

    Biotechnology company focused on the development of novel treatments for cancer
    • Year Invested

      2002
    • Fund

      I
    • Sector

      Biopharma
    • Company Status

      acquired
    • Investment Status

      historic
    • Location

      Tarrytown, NY
    • Website

      merck.com
  • Auxilium Pharmaceuticals, Inc.

    NasdaqGS:AUXL
    Specialty pharmaceutical company that develops and markets pharmaceutical products for urology and sexual health
    • Year Invested

      2003
    • Fund

      I
    • Sector

      Biopharma
    • Company Status

      public
    • Investment Status

      historic
    • Location

      Chesterbrook, PA
    • Website

      auxilium.com
  • AVANZA Laboratories, LLC

    Contract research organization that provides GLP complaint drug development services for biotechnology and pharmaceutical firms, and government agencies
    • Year Invested

      2009
    • Fund

      II
    • Sector

      Services
    • Company Status

      acquired
    • Investment Status

      historic
    • Location

      Gaithersburg, MD
    • Website

      smithersavanza.com
  • Axcan Pharma, Inc.

    Specialty pharmaceutical company focused on the treatment of gastrointestinal disorders
    • Year Invested

      2000
    • Fund

      I
    • Sector

      Biopharma
    • Company Status

      acquired
    • Investment Status

      historic
    • Location

      Quebec, Canada
    • Website

      actavis.com
  • Barrier Therapeutics, Inc.

    Specialty pharmaceutical company focused on development and commercialization of dermatology drugs
    • Year Invested

      2002
    • Fund

      I
    • Sector

      Biopharma
    • Company Status

      acquired
    • Investment Status

      historic
    • Location

      Princeton, NJ
    • Website

      stiefel.com
  • Bioenvision, Inc.

    Biotechnology company focused on the development and commercialization of drugs to treat oncology and infectious disease
    • Year Invested

      2002
    • Fund

      I
    • Sector

      Biopharma
    • Company Status

      acquired
    • Investment Status

      historic
    • Location

      New York, NY
    • Website

      genzyme.com
  • Cardiokine, Inc.

    Biotechnology company developing drugs for the treatment and prevention of cardiovascular diseases
    • Year Invested

      2004
    • Fund

      I
    • Sector

      Biopharma
    • Company Status

      acquired
    • Investment Status

      historic
    • Location

      Philadelphia, PA
    • Website

      chiesiusa.com
  • Catalent, Inc.

    NYSE:CTLT
    Provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products
    • Year Invested

      2007
    • Fund

      II
    • Sector

      Services
    • Company Status

      public
    • Investment Status

      current
    • Location

      Somerset, NJ
    • Website

      catalent.com
  • Cempra, Inc.

    NasdaqGS:CEMP
    Drug discovery and development company focused on infectious diseases and the treatment of drug-resistant bacteria
    • Year Invested

      2006
    • Fund

      II
    • Sector

      Biopharma
    • Company Status

      public
    • Investment Status

      current
    • Location

      Chapel Hill, NC
    • Website

      cempra.com
  • Chimerix, Inc.

    NasdaqGM:CMRX
    Biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need
    • Year Invested

      2013
    • Fund

      III
    • Sector

      Biopharma
    • Company Status

      public
    • Investment Status

      current
    • Location

      Durham, NC
    • Website

      chimerix.com
  • Cidara Therapeutics, Inc.

    Drug discovery and development company focused on devastating fungal infections that often complicate cancer and transplant treatments
    • Year Invested

      2008
    • Fund

      II
    • Sector

      Biopharma
    • Company Status

      private
    • Investment Status

      current
    • Location

      San Diego, CA
    • Website

      cidara.com
  • Clovis Oncology, Inc.

    NasdaqGS:CLVS
    Biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents
    • Year Invested

      2011
    • Fund

      III
    • Sector

      Biopharma
    • Company Status

      public
    • Investment Status

      historic
    • Location

      Boulder, CO
    • Website

      clovisoncology.com
  • CollaGenex Pharmaceuticals, Inc.

    Specialty pharmaceutical company that develops and markets proprietary medical therapies to the dermatology market
    • Year Invested

      2001
    • Fund

      I
    • Sector

      Biopharma
    • Company Status

      acquired
    • Investment Status

      historic
    • Location

      Newton, PA
    • Website

      galderma.com
  • Colorescience, Inc.

    Cosmetics company that manufactures and sells mineral-based products
    • Year Invested

      2012
    • Fund

      I
    • Sector

      Consumer
    • Company Status

      acquired
    • Investment Status

      historic
    • Location

      Carlsbad, CA
    • Website

      colorescience.com
  • Cytos Biotechnology AG

    SWX:CYTN
    Biopharmaceutical company focused on the development of targeted immunotherapies with a VLP B-cell vaccines platform and ongoing preclinical development programs based on the platform
    • Year Invested

      2012
    • Fund

      III
    • Sector

      Biopharma
    • Company Status

      public
    • Investment Status

      current
    • Location

      Schlieren, Switzerland
    • Website

      cytos.com
  • Dermira, Inc.

    NasdaqGS:DERM
    Specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients
    • Year Invested

      2014
    • Fund

      III
    • Sector

      Biopharma
    • Company Status

      public
    • Investment Status

      current
    • Location

      Redwood City, CA
    • Website

      dermira.com
  • Durata Therapeutics, Inc.

    Pharmaceutical company focused on the development and commercialization of differentiated therapeutic solutions for physicians and providers to advance patient care in infectious disease and acute illnesses
    • Year Invested

      2009
    • Fund

      III
    • Sector

      Biopharma
    • Company Status

      acquired
    • Investment Status

      historic
    • Location

      Chicago, IL
    • Website

      duratatherapeutics.com
  • EarLens Corporation

    Medical device company committed to providing hearing impaired patients a hearing solution that is designed to change the current standard of care for sound performance.
    • Year Invested

      2014
    • Fund

      III
    • Sector

      Medical Device
    • Company Status

      private
    • Investment Status

      current
    • Location

      Menlo Park, CA
    • Website

      earlenscorp.com
  • Esperion Therapeutics, Inc.

    NasdaqGM:ESPR
    Drug discovery and development company focused on therapies that prevent, treat and reverse cardiovascular and metabolic diseases
    • Year Invested

      2008
    • Fund

      II
    • Sector

      Biopharma
    • Company Status

      public
    • Investment Status

      current
    • Location

      Ann Arbor, MI
    • Website

      esperion.com
  • Ibrutinib Royalty

    Anti-cancer drug targeting B-cell malignancies
    • Year Invested

      2013
    • Fund

      III
    • Sector

      Biopharma
    • Company Status

      private
    • Investment Status

      current
    • Location

      N/A
    • Website

      imbruvica.com
  • Infinity Pharmaceuticals, Inc.

    NasdaqGS:INFI
    Biopharmaceutical company dedicated to discovering, developing and delivering best-in-class medicines to patients with difficult-to-treat diseases
    • Year Invested

      2012
    • Fund

      III
    • Sector

      Biopharma
    • Company Status

      public
    • Investment Status

      historic
    • Location

      Cambridge, MA
    • Website

      infi.com
  • Intercept Pharmaceuticals, Inc.

    NasdaqGS:ICPT
    Biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing our proprietary bile acid chemistry
    • Year Invested

      2012
    • Fund

      III
    • Sector

      Biopharma
    • Company Status

      public
    • Investment Status

      historic
    • Location

      New York, NY
    • Website

      interceptpharma.com
  • Intersect ENT, Inc.

    NasdaqGM:XENT
    Commercial stage drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions
    • Year Invested

      2014
    • Fund

      III
    • Sector

      Medical Device
    • Company Status

      public
    • Investment Status

      current
    • Location

      Menlo Park, CA
    • Website

      propelopens.com
  • LENSAR, Inc.

    Leader in next-generation femtosecond laser technology for refractive cataract surgery
    • Year Invested

      2008
    • Fund

      II
    • Sector

      Medical Device
    • Company Status

      private
    • Investment Status

      current
    • Location

      Orlando, FL
    • Website

      lensar.com
  • Lombard Medical, Inc.

    NasdaqGM:EVAR
    Medical technology company specializing in developing, manufacturing and marketing endovascular stent-grafts that address significant unmet needs in the repair of aortic aneurysms
    • Year Invested

      2014
    • Fund

      III
    • Sector

      Medical Device
    • Company Status

      public
    • Investment Status

      current
    • Location

      Oxfordshire, UK
    • Website

      lombardmedical.com
  • Loxo Oncology, Inc.

    NasdaqGM:LOXO
    Biotechnology company developing targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations
    • Year Invested

      2013
    • Fund

      III
    • Sector

      Biopharma
    • Company Status

      public
    • Investment Status

      current
    • Location

      Stamford, CT
    • Website

      loxooncology.com
  • MAP Pharmaceuticals, Inc.

    Specialty pharmaceutical company developing new therapies based on proprietary drug particle and inhalation technologies
    • Year Invested

      2003
    • Fund

      I
    • Sector

      Biopharma
    • Company Status

      acquired
    • Investment Status

      historic
    • Location

      Mountain View, CA
    • Website

      allergan.com
  • MEI Pharma, Inc.

    NasdaqCM:MEIP
    Oncology company focused on the clinical development of novel therapies for cancer
    • Year Invested

      2013
    • Fund

      III
    • Sector

      Biopharma
    • Company Status

      public
    • Investment Status

      current
    • Location

      San Diego, CA
    • Website

      meipharma.com
  • Miramar Labs, Inc.

    Medical device company focused on developing products for dermatologic medical conditions
    • Year Invested

      2011
    • Fund

      III
    • Sector

      Medical Device
    • Company Status

      private
    • Investment Status

      current
    • Location

      Sunnyvale, CA
    • Website

      miradry.com
  • Myogen, Inc.

    Biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders
    • Year Invested

      2001
    • Fund

      I
    • Sector

      Biopharma
    • Company Status

      acquired
    • Investment Status

      historic
    • Location

      Westminster, CO
    • Website

      gilead.com
  • NextWave Pharmaceuticals, Inc.

    Specialty pharmaceutical company developing extended release OTC and prescription products for children and adults
    • Year Invested

      2007
    • Fund

      II
    • Sector

      Biopharma
    • Company Status

      acquired
    • Investment Status

      historic
    • Location

      Cupertino, CA
    • Website

      pfizer.com
  • Novazyme Pharmaceuticals, Inc.

    Biotechnology company focused on drugs to treat lysosomal storage diseases
    • Year Invested

      2000
    • Fund

      I
    • Sector

      Biopharma
    • Company Status

      acquired
    • Investment Status

      historic
    • Location

      Princeton, NJ
    • Website

      genzyme.com
  • Oculex Pharmaceuticals, Inc.

    Ophthalmic drug delivery company with platform technology to facilitate the treatment of major sight-threatening eye diseases and conditions
    • Year Invested

      2002
    • Fund

      I
    • Sector

      Medical Device
    • Company Status

      acquired
    • Investment Status

      historic
    • Location

      Sunnyvale, CA
    • Website

      allergan.com
  • Paratek Pharmaceuticals, Inc.

    NasdaqGM:PRTK
    Biopharmaceutical company engaged in the discovery, development and commercialization of antibiotics to save lives and alleviate suffering
    • Year Invested

      2007
    • Fund

      II
    • Sector

      Biopharma
    • Company Status

      public
    • Investment Status

      current
    • Location

      Boston, MA
    • Website

      paratekpharm.com
  • Pernix Therapeutics, Inc.

    NasdaqGM:PTX
    Specialty pharmaceutical company primarily focused on the sales, marketing and development of branded pharmaceutical products
    • Year Invested

      2011
    • Fund

      III
    • Sector

      Biopharma
    • Company Status

      public
    • Investment Status

      current
    • Location

      Houston, TX
    • Website

      pernixtx.com
  • Pharmaron, Inc.

    Provider of research and development services for pharmaceutical and biotechnological industries worldwide
    • Year Invested

      2006
    • Fund

      II
    • Sector

      Services
    • Company Status

      private
    • Investment Status

      current
    • Location

      Beijing, China
    • Website

      pharmaron.com
  • Planet Biopharmaceuticals, Inc.

    Developer and manufacturer of allergenic extracts and other products for the treatment and prevention of allergy
    • Year Invested

      2007
    • Fund

      II
    • Sector

      Consumer
    • Company Status

      acquired
    • Investment Status

      historic
    • Location

      Liberty, MO
    • Website

      areslifesciences.com
  • PowerVision, Inc.

    Developer of a fluid-controlled intraocular lens
    • Year Invested

      2014
    • Fund

      III
    • Sector

      Medical Device
    • Company Status

      private
    • Investment Status

      current
    • Location

      Belmont, CA
    • Website

      powevisionlens.com
  • PreCision Dermatology, Inc.

    Specialty pharmaceutical company developing, manufacturing and marketing prescription and consumer dermatology products
    • Year Invested

      2012
    • Fund

      III
    • Sector

      Biopharma
    • Company Status

      acquired
    • Investment Status

      historic
    • Location

      Cumberland, RI
    • Website

      valeant.com
  • Quintiles Transnational Holdings Inc.

    NYSE:Q
    Contract pharmaceutical research and sales organization
    • Year Invested

      2003
    • Fund

      I
    • Sector

      Services
    • Company Status

      public
    • Investment Status

      historic
    • Location

      Durham, NC
    • Website

      quintiles.com
  • Roka Bioscience, Inc.

    NasdaqGM:ROKA
    Molecular diagnostics company focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens
    • Year Invested

      2011
    • Fund

      III
    • Sector

      Diagnostics
    • Company Status

      public
    • Investment Status

      current
    • Location

      Warren, NJ
    • Website

      rokabio.com
  • Seragon Pharmaceuticals, Inc.

    Biopharmaceutical company focused on developing drugs for the treatment of estrogen receptor dependent breast cancer
    • Year Invested

      2013
    • Fund

      III
    • Sector

      Biopharma
    • Company Status

      acquired
    • Investment Status

      historic
    • Location

      San Diego, CA
    • Website

      gene.com
  • Sirion Therapeutics, Inc.

    Ophthalmic-focused biopharmaceutical company engaged in the discovery, development and commercialization of products for the protection and preservation of eyesight
    • Year Invested

      2007
    • Fund

      II
    • Sector

      Biopharma
    • Company Status

      acquired
    • Investment Status

      historic
    • Location

      Tampa, FL
    • Website

      N/A
  • SkinMedica, Inc.

    Specialty pharmaceutical company focused on development and commercialization of dermatology drugs and cosmeceuticals
    • Year Invested

      2004
    • Fund

      I
    • Sector

      Consumer
    • Company Status

      acquired
    • Investment Status

      historic
    • Location

      Carlsbad, CA
    • Website

      skinmedica.com
  • Sorrento Therapeutics, Inc.

    NasdaqCM:SRNE
    Biopharmaceutical company engaged in the discovery, acquisition, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs
    • Year Invested

      2013
    • Fund

      III
    • Sector

      Biopharma
    • Company Status

      public
    • Investment Status

      current
    • Location

      San Diego, CA
    • Website

      sorrentotherapeutics.com
  • Syros Pharmaceuticals, Inc.

    Life sciences company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases
    • Year Invested

      2014
    • Fund

      III
    • Sector

      Biopharma
    • Company Status

      private
    • Investment Status

      current
    • Location

      Watertown, MA
    • Website

      syros.com
  • T2 Biosystems, Inc.

    NasdaqGM:TTOO
    In vitro diagnostics company that has developed a technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies
    • Year Invested

      2011
    • Fund

      III
    • Sector

      Diagnostics
    • Company Status

      public
    • Investment Status

      current
    • Location

      Lexington, MA
    • Website

      t2biosystems.com
  • Topaz Pharmaceuticals, Inc.

    Specialty pharmaceutical company focused on developing and commercializing treatments primarily for the pediatric and dermatology markets.
    • Year Invested

      2007
    • Fund

      II
    • Sector

      Biopharma
    • Company Status

      acquired
    • Investment Status

      historic
    • Location

      Horsham, PA
    • Website

      sanofi.us
  • TransEnterix, Inc.

    NYSEMKT:TRXC
    Medical device company that is focused on the development and commercialization of manual and robotic assisted surgical systems for minimally invasive surgery
    • Year Invested

      2009
    • Fund

      III
    • Sector

      Medical Device
    • Company Status

      public
    • Investment Status

      current
    • Location

      Morrisville, NC
    • Website

      transenterix.com
  • TRIA Beauty, Inc.

    Medical device company developing and commercializing at-home, light-based skincare products
    • Year Invested

      2008
    • Fund

      II
    • Sector

      Consumer
    • Company Status

      private
    • Investment Status

      current
    • Location

      Dublin, CA
    • Website

      triabeauty.com
  • Versartis, Inc.

    NasdaqGS:VSAR
    Endocrine-focused biopharmaceutical company developing novel long-acting recombinant human growth hormone for growth hormone deficiency
    • Year Invested

      2013
    • Fund

      III
    • Sector

      Biopharma
    • Company Status

      public
    • Investment Status

      current
    • Location

      Redwood City, CA
    • Website

      versartis.com
  • ViewRay, Inc.

    Medical device company developing advanced radiation therapy technology for the treatment of cancer
    • Year Invested

      2008
    • Fund

      II
    • Sector

      Medical Device
    • Company Status

      private
    • Investment Status

      current
    • Location

      Oakwood Village, OH
    • Website

      viewray.com
  • VIVUS, Inc.

    NasdaqGS:VVUS
    Biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, sleep apnea and sexual health
    • Year Invested

      2006
    • Fund

      II
    • Sector

      Biopharma
    • Company Status

      public
    • Investment Status

      historic
    • Location

      Mountain View, CA
    • Website

      vivus.com
  • ZELTIQ Aesthetics, Inc.

    NasdaqGS:ZLTQ
    Medical technology company focused on developing and commercializing products utilizing a controlled cooling technology platform for non-invasive fat reduction
    • Year Invested

      2010
    • Fund

      III
    • Sector

      Consumer
    • Company Status

      public
    • Investment Status

      current
    • Location

      Pleasanton, CA
    • Website

      coolsculpting.com